Clarity Medical Group Holding Limited reported a turnaround in operating momentum for the quarter ended 31 March 2026, with revenue rising 2.40% year-on-year after prior declines of 8.40% in Q2 and 6.60% in Q3 of FY2026. Management attributed the recovery to diminishing impact from past allegations and renewed focus on core ophthalmic services.

March 2026 delivered the highest monthly revenue and booking volume since 2024, led by record implantable collamer lens (ICL) bookings, reinforcing the group’s leading market share in Hong Kong refractive surgery.

Professional fees related to ongoing legal and investigative matters remained “substantial” during Q4, but the company expects these costs to fall materially as cases conclude and plans to pursue recovery of related losses.

On governance, FTI Consulting completed its independent investigation, finding no evidence of fraudulent or dishonest acts by current directors or senior management. A separate forensic review by Grant Thornton Advisory Services is in its advanced stage under legal supervision.

A Big Four firm has been engaged to conduct an independent internal-control review, while the company states full compliance with earlier corporate-governance guidance. Chairman of the Separate Special Committee, Mr. Lee Kam Hung Lawrence, resigned on 13 April 2026 due to personal commitments but may serve as a consultant; management does not expect his departure to affect the investigation’s progress.

Auditor Ernst & Young resigned effective 31 March 2026. Crowe (HK) CPA Limited is undergoing engagement acceptance procedures to fill the vacancy. As a result, publication of FY2025 audited results and the interim results for the six months ended 30 September 2025 remains delayed. The board maintains that these delays have no material adverse impact on day-to-day operations.

Clarity Medical states continual compliance with Listing Rule 13.24, citing substantive operations and cost-control initiatives. Trading in the company’s shares has been suspended since 15 April 2025 and will remain halted until all resumption guidance—covering allegations investigation, integrity, internal control, corporate governance, disclosure, financial reporting and Rule 13.24—has been fully satisfied. Shareholders are advised to exercise caution when dealing in the company’s securities.